TRNT1 Antibody

Shipped with Ice Packs
In Stock

Product Specs

Buffer
Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, pH 7.4
Form
Liquid
Lead Time
Made-to-order (14-16 weeks)
Synonyms
TRNT1 antibody; CGI-47 antibody; CCA tRNA nucleotidyltransferase 1 antibody; mitochondrial antibody; EC 2.7.7.72 antibody; Mitochondrial tRNA nucleotidyl transferase antibody; CCA-adding antibody; mt CCA-adding enzyme antibody; mt tRNA CCA-diphosphorylase antibody; mt tRNA CCA-pyrophosphorylase antibody; mt tRNA adenylyltransferase antibody
Target Names
TRNT1
Uniprot No.

Target Background

Function
This enzyme catalyzes the addition and repair of the conserved 3'-CCA sequence essential for amino acid attachment to the 3' terminus of tRNA molecules, utilizing CTP and ATP as substrates. This specific isoform adds two C residues (CC-) to the 3' terminus of tRNA molecules instead of a complete CCA end, as isoform 1 does (in vitro).
Gene References Into Functions
  1. In vitro studies on disease-linked variants of human tRNA nucleotidyltransferase have revealed decreased thermal stability and altered catalytic activity. PMID: 29454993
  2. Patient-specific induced pluripotent stem cells (iPSCs) and iPSC-derived retinal organoids from dermal fibroblasts of patients with molecularly confirmed TRNT1-associated retinitis pigmentosa were used in research. PMID: 28390992
  3. Data indicates that disease-causing mutations in patient-derived fibroblasts do not affect the subcellular localization of TRNT1 and exhibit no gross morphological differences compared to control cells. PMID: 27317422
  4. This research expands the ocular and systemic phenotypes associated with mutations in TRNT1, highlighting phenotypic variability and emphasizing the need for ophthalmic review of these patients. PMID: 27389523
  5. Two non-syndromic retinitis pigmentosa pedigrees with segregating mutations in TRNT1 were studied. PMID: 26494905
  6. The clinical phenotypes associated with TRNT1 mutations are primarily attributed to impaired mitochondrial translation, arising from defective CCA addition to mitochondrial tRNA(Ser(AGY)). PMID: 25652405
  7. A model of action is proposed, suggesting that motif C acts as a flexible spring element modulating the relative orientation of the enzyme's head and body domains to accommodate the growing 3'-end of the tRNA. PMID: 25849199
  8. The discriminator base serves as a crucial substrate recognition element for tRNA nucleotidyltransferases. PMID: 25958396
  9. Tandem CCA addition is not a result of a modified enzymatic activity specific to unstable RNAs. It is instead a consequence of the natural activity of the CCA-adding enzyme on a substrate with increased conformational flexibility. The CCA-adding enzyme has the ability to trigger the degradation of potentially detrimental small RNAs and tRNAs. PMID: 25640237
  10. Patient-associated TRNT1 mutations lead to partial loss of function of TRNT1, resulting in metabolic defects in both mitochondria and cytosol, which can account for the phenotypic pleiotropy. PMID: 25193871
  11. Human gene transcript CGI-47 (#AF151805) was cloned and encodes a bona fide CCA-adding enzyme, not a poly(A) polymerase. PMID: 11727826
  12. The crystal structure reveals a four-domain architecture with a cluster of conserved residues forming a positively charged cleft between the first two domains. PMID: 12729736
  13. These findings strongly suggest that the splice variant of the human CCA-adding enzyme is expressed in the cell, although its in vivo function remains unclear. PMID: 17204286
  14. TRNT1 is an RNA polymerase that adds a CCA sequence to the 3' terminal of tRNA. This reaction has been termed Vice-Anchored Knock-in and Lock Dynamics. [review] PMID: 18575231

Show More

Hide All

Database Links

HGNC: 17341

OMIM: 612907

KEGG: hsa:51095

STRING: 9606.ENSP00000251607

UniGene: Hs.732725

Involvement In Disease
Sideroblastic anemia with B-cell immunodeficiency, periodic fevers, and developmental delay (SIFD); Retinitis pigmentosa and erythrocytic microcytosis (RPEM)
Protein Families
TRNA nucleotidyltransferase/poly(A) polymerase family
Subcellular Location
Mitochondrion.

Q&A

Basic Research Questions

  • What experimental validation strategies ensure TRNT1 antibody specificity in tissue-specific contexts?

    • Perform parallel validation via:

      1. Knockdown/knockout controls (e.g., siRNA-mediated TRNT1 suppression in HepG2 cells )

      2. Western blotting against recombinant TRNT1 protein (48 kDa band confirmation )

      3. Cross-reactivity screening using TRNT1-deficient fibroblast lines .

    • Key data: Antibody dilution ranges (IHC: 1:50–1:500; IF: 1:50–1:500) require titration for tissue-specific antigen retrieval (TE buffer pH 9.0 vs. citrate pH 6.0 ).

  • How to optimize TRNT1 antibody protocols for mitochondrial vs. cytosolic tRNA studies?

    • Use subcellular fractionation paired with immunoblotting to distinguish mitochondrial vs. cytosolic TRNT1 isoforms.

    • Combine with tRNA stability assays (e.g., NaAsO₂-induced oxidative stress models ).

Advanced Research Questions

  • How to address inconsistencies in TRNT1 protein detection across cell lines (e.g., fibroblasts vs. cancer cells)?

    • Methodological steps:

      • Validate antibody batch consistency via ELISA (human/mouse reactivity ).

      • Adjust fixation methods (e.g., methanol vs. paraformaldehyde) to preserve epitopes in nuclear/cytoplasmic compartments .

      • Use mass spectrometry to confirm TRNT1 isoform expression in discrepant models .

  • What computational tools complement TRNT1 antibody-based studies in tRNA processing analysis?

    • Integrate RNA-seq with TRNT1 immunoprecipitation data to map tRNA cleavage sites (e.g., tiRNA accumulation under oxidative stress ).

    • Tools:

      ToolApplicationReference
      ELNETClassifier construction for CpG methylation
      GSEAPathway enrichment in tRNA stability

Methodological Case Studies

  • Resolving TRNT1 antibody aggregation in long-term storage

    • Approach:

      • Pre-aliquot antibodies with 0.1% BSA to mitigate freeze-thaw damage .

      • Monitor aggregation via dynamic light scattering (DLS) and compare with clinical-grade antibody stability benchmarks .

  • Interpreting TRNT1 expression variability in siRNA knockdown models

    • Key findings:

      • TRNT1 siRNA reduces protein levels by 60–70% in fibroblasts, but residual activity persists due to mitochondrial isoforms .

      • Combine antibody staining with functional assays (e.g., tRNA aminoacylation rates ).

Data Contradiction Analysis

  • Discrepancies in TRNT1 antibody reactivity between IHC and IF

    • Root cause:

      • Epitope masking in formalin-fixed tissues vs. live-cell IF .

    • Solution:

      • Antigen retrieval optimization (pH 9.0 TE buffer enhances epitope exposure in skeletal muscle ).

Quick Inquiry

Personal Email Detected
Please use an institutional or corporate email address for inquiries. Personal email accounts ( such as Gmail, Yahoo, and Outlook) are not accepted. *
© Copyright 2025 TheBiotek. All Rights Reserved.